Pharmaceutical Research

, Volume 29, Issue 1, pp 35–52

Cellular Reprogramming: A New Technology Frontier in Pharmaceutical Research

Authors

  • Amy Brock
    • Wyss Institute for Biologically Inspired EngineeringHarvard University
  • Hui-Tong Goh
    • Epigenetics & Cell Fates LaboratoryA*STAR Institute of Medical Biology
  • Binxia Yang
    • Epigenetics & Cell Fates LaboratoryA*STAR Institute of Medical Biology
  • Yu Lu
    • Department of Biological Chemistry & Molecular PharmacologyHarvard Medical School
    • Wyss Institute for Biologically Inspired EngineeringHarvard University
    • Department of Biomedical Engineering & Center for BioDynamicsBoston University
    • Wyss Institute, Harvard Medical School
    • Epigenetics & Cell Fates LaboratoryA*STAR Institute of Medical Biology
    • Department of Biological SciencesNational University of Singapore
Expert Review

DOI: 10.1007/s11095-011-0618-z

Cite this article as:
Brock, A., Goh, H., Yang, B. et al. Pharm Res (2012) 29: 35. doi:10.1007/s11095-011-0618-z

Abstract

Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

Key Words

cellular reprogrammingdrug discoveryiPSCpharmaceutical researchstem cells

Copyright information

© Springer Science+Business Media, LLC 2011